Guillain-Barre Syndrome (GBS) - Market Insight, Epidemiology, and Market Forecast - 2034
이 보고서는 미국, 독일, 스페인, 이탈리아, 프랑스, 영국, 일본 등 주요 7개국(미국, 독일, 스페인, 이탈리아, 프랑스, 영국, 일본)의 길랭 바레 증후군(GBS) 시장을 조사 분석하여 각 지역의 시장 규모, 현재 치료법, 미충족 수요, 새로운 치료법 등에 대한 정보를 제공합니다.
목차
제1장 주요 인사이트
제2장 길랭 바레 증후군(GBS) 주요 요약
제3장 길랭 바레 증후군(GBS) 경쟁 정보 분석
제4장 길랭 바레 증후군(GBS) : 시장 개요
- 길랭 바레 증후군(GBS) 전체 시장 점유율 분포(2020년)
- 길랭 바레 증후군(GBS) 전체 시장 점유율 분포(2034년)
제5장 길랭 바레 증후군(GBS) : 질환 배경과 개요
제6장 환자 여정
제7장 길랭 바레 증후군(GBS) 역학과 환자 인구
- 역학의 주요 조사 결과
- 가정과 근거 : 주요 7개 시장
- 역학 시나리오 : 주요 7개 시장
- 주요 7개 시장의 길랭 바레 증후군(GBS) 역학 시나리오(2020-2034년)
- 미국의 역학
- 미국의 길랭 바레 증후군(GBS) 역학 시나리오(2020-2034년)
- 유럽 5개국의 역학 : 국가별
- 독일의 역학
- 프랑스의 역학
- 이탈리아의 역학
- 스페인의 역학
- 영국의 역학
- 일본의 역학
제8장 치료 알고리즘, 현재 치료, 의료 행위
- 길랭 바레 증후군(GBS) 치료와 관리
- 길랭 바레 증후군(GBS) 치료 알고리즘
제9장 미충족 수요
제10장 길랭 바레 증후군(GBS) 치료의 주요 평가 항목
제11장 출시된 제품
제12장 새로운 치료법
제13장 길랭 바레 증후군(GBS) : 주요 7개 시장 분석
- 주요 조사 결과
- 주요 7개 시장의 길랭 바레 증후군(GBS) 시장 규모
- 주요 7개 시장의 길랭 바레 증후군(GBS) 시장 규모 : 치료법별
제14장 속성 분석
제15장 주요 7개 시장 : 시장 전망
- 미국 : 시장 규모
- 미국의 길랭 바레 증후군(GBS) 전체 시장 규모
- 미국의 길랭 바레 증후군(GBS) 시장 규모 : 치료법별
- 유럽 5개국 : 시장 규모와 전망
- 독일의 시장 규모
- 독일의 길랭 바레 증후군(GBS) 전체 시장 규모
- 독일의 길랭 바레 증후군(GBS) 시장 규모 : 치료법별
- 프랑스의 시장 규모
- 이탈리아의 시장 규모
- 스페인의 시장 규모
- 영국의 시장 규모
- 영국의 길랭 바레 증후군(GBS) 전체 시장 규모
- 영국의 길랭 바레 증후군(GBS) 시장 규모 : 치료법별
- 일본 시장 전망
제16장 길랭 바레 증후군(GBS) 액세스와 상환 개요
제17장 KOL의 견해
제18장 시장 성장 촉진요인
제19장 시장 장벽
제20장 부록
제21장 DelveInsight의 서비스 내용
제22장 면책사항
제23장 DelveInsight 소개
ksm
DelveInsight's "Guillain-Barre Syndrome (GBS) - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Guillain-Barre Syndrome (GBS), historical and forecasted epidemiology as well as the Guillain-Barre Syndrome (GBS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Guillain-Barre Syndrome (GBS) market report provides current treatment practices, emerging drugs, Guillain-Barre Syndrome (GBS) market share of the individual therapies, current and forecasted Guillain-Barre Syndrome (GBS) market size from 2020 to 2034 segmented by seven major markets. The Report also covers current Guillain-Barre Syndrome (GBS) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Geography Covered:
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2020-2034
Guillain-Barre Syndrome (GBS) Disease Understanding and Treatment Algorithm
The DelveInsight Guillain-Barre Syndrome (GBS) market report gives a thorough understanding of the Guillain-Barre Syndrome (GBS) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.
Diagnosis
This segment of the report covers the detailed diagnostic methods or tests for Guillain-Barre Syndrome (GBS).
Treatment
It covers the details of conventional and current medical therapies available in the Guillain-Barre Syndrome (GBS) market for the treatment of the condition. It also provides Guillain-Barre Syndrome (GBS) treatment algorithms and guidelines in the United States, Europe, and Japan.
Guillain-Barre Syndrome (GBS) Epidemiology
The Guillain-Barre Syndrome (GBS) epidemiology division provide insights about historical and current Guillain-Barre Syndrome (GBS) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Guillain-Barre Syndrome (GBS) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.
Country Wise-Guillain-Barre Syndrome (GBS) Epidemiology
The epidemiology segment also provides the Guillain-Barre Syndrome (GBS) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Guillain-Barre Syndrome (GBS) Drug Chapters
Drug chapter segment of the Guillain-Barre Syndrome (GBS) report encloses the detailed analysis of Guillain-Barre Syndrome (GBS) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Guillain-Barre Syndrome (GBS) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Marketed Drugs
The report provides the details of the marketed product available for Guillain-Barre Syndrome (GBS) treatment.
Guillain-Barre Syndrome (GBS) Emerging Drugs
The report provides the details of the emerging therapies under the late and mid-stage of development for Guillain-Barre Syndrome (GBS) treatment.
Guillain-Barre Syndrome (GBS) Market Outlook
The Guillain-Barre Syndrome (GBS) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Guillain-Barre Syndrome (GBS) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of Guillain-Barre Syndrome (GBS) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, Guillain-Barre Syndrome (GBS) market in 7MM is expected to change in the study period 2020-2034.
Key Findings
This section includes a glimpse of the Guillain-Barre Syndrome (GBS) market in 7MM.
The United States Market Outlook
This section provides the total Guillain-Barre Syndrome (GBS) market size and market size by therapies in the United States.
EU-5 Countries: Market Outlook
The total Guillain-Barre Syndrome (GBS) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.
Japan Market Outlook
The total Guillain-Barre Syndrome (GBS) market size and market size by therapies in Japan is also mentioned.
Guillain-Barre Syndrome (GBS) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the Guillain-Barre Syndrome (GBS) market or expected to get launched in the market during the study period 2020-2034. The analysis covers Guillain-Barre Syndrome (GBS) market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Guillain-Barre Syndrome (GBS) Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Guillain-Barre Syndrome (GBS) key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Guillain-Barre Syndrome (GBS) emerging therapies.
Reimbursement Scenario in Guillain-Barre Syndrome (GBS)
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
KOL- Views
To keep up with current market trends, we take KOLs and SME's opinion working in Guillain-Barre Syndrome (GBS) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Guillain-Barre Syndrome (GBS) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Guillain-Barre Syndrome (GBS) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report:
- The report covers the descriptive overview of Guillain-Barre Syndrome (GBS), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Guillain-Barre Syndrome (GBS) epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Guillain-Barre Syndrome (GBS) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of Guillain-Barre Syndrome (GBS) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Guillain-Barre Syndrome (GBS) market
Report Highlights:
- In the coming years, Guillain-Barre Syndrome (GBS) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- The companies and academics are working to assess challenges and seek opportunities that could influence Guillain-Barre Syndrome (GBS) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- Major players are involved in developing therapies for Guillain-Barre Syndrome (GBS). Launch of emerging therapies will significantly impact the Guillain-Barre Syndrome (GBS) market
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Guillain-Barre Syndrome (GBS)
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Guillain-Barre Syndrome (GBS) Report Insights
- Patient Population
- Therapeutic Approaches
- Guillain-Barre Syndrome (GBS) Pipeline Analysis
- Guillain-Barre Syndrome (GBS) Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Guillain-Barre Syndrome (GBS) Report Key Strengths
- 11 Years Forecast
- 7MM Coverage
- Guillain-Barre Syndrome (GBS) Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Guillain-Barre Syndrome (GBS) Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
Key Questions:
Market Insights:
- What was the Guillain-Barre Syndrome (GBS) market share (%) distribution in 2020 and how it would look like in 2034?
- What would be the Guillain-Barre Syndrome (GBS) total market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
- What are the key findings pertaining to the market across 7MM and which country will have the largest Guillain-Barre Syndrome (GBS) market size during the forecast period (2024-2034)?
- At what CAGR, the Guillain-Barre Syndrome (GBS) market is expected to grow in 7MM during the forecast period (2020-2034)?
- What would be the Guillain-Barre Syndrome (GBS) market outlook across the 7MM during the forecast period (2020-2034)?
- What would be the Guillain-Barre Syndrome (GBS) market growth till 2032, and what will be the resultant market Size in the year 2034?
- How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
- What is the disease risk, burden and unmet needs of the Guillain-Barre Syndrome (GBS)?
- What is the historical Guillain-Barre Syndrome (GBS) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What would be the forecasted patient pool of Guillain-Barre Syndrome (GBS) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Guillain-Barre Syndrome (GBS)?
- Out of all 7MM countries, which country would have the highest prevalent population of Guillain-Barre Syndrome (GBS) during the forecast period (2020-2034)?
- At what CAGR the population is expected to grow in 7MM during the forecast period (2020-2034)?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
- What are the current options for the Guillain-Barre Syndrome (GBS) treatment, along with the approved therapy?
- What are the current treatment guidelines for the treatment of Guillain-Barre Syndrome (GBS) in the USA, Europe, and Japan?
- What are the Guillain-Barre Syndrome (GBS) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
- How many companies are developing therapies for the treatment of Guillain-Barre Syndrome (GBS)?
- How many therapies are developed by each company for Guillain-Barre Syndrome (GBS) treatment?
- How many are emerging therapies in mid-stage, and late stage of development for Guillain-Barre Syndrome (GBS) treatment?
- What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Guillain-Barre Syndrome (GBS) therapies?
- What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Guillain-Barre Syndrome (GBS) and their status?
- What are the key designations that have been granted for the emerging therapies for Guillain-Barre Syndrome (GBS)?
- What are the global historical and forecasted market of Guillain-Barre Syndrome (GBS)?
Reasons to buy:
- The report will help in developing business strategies by understanding trends shaping and driving the Guillain-Barre Syndrome (GBS) market
- To understand the future market competition in the Guillain-Barre Syndrome (GBS) market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Guillain-Barre Syndrome (GBS) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for Guillain-Barre Syndrome (GBS) market
- To understand the future market competition in the Guillain-Barre Syndrome (GBS) market
Table of Contents
1. Key Insights
2. Executive Summary of Guillain-Barre Syndrome (GBS)
3. Competitive Intelligence Analysis for Guillain-Barre Syndrome (GBS)
4. Guillain-Barre Syndrome (GBS): Market Overview at a Glance
- 4.1. Guillain-Barre Syndrome (GBS) Total Market Share (%) Distribution in 2020
- 4.2. Guillain-Barre Syndrome (GBS) Total Market Share (%) Distribution in 2034
5. Guillain-Barre Syndrome (GBS): Disease Background and Overview
- 5.1. Introduction
- 5.2. Sign and Symptoms
- 5.3. Pathophysiology
- 5.4. Risk Factors
- 5.5. Diagnosis
6. Patient Journey
7. Guillain-Barre Syndrome (GBS) Epidemiology and Patient Population
- 7.1. Epidemiology Key Findings
- 7.2. Assumptions and Rationale: 7MM
- 7.3. Epidemiology Scenario: 7MM
- 7.3.1. Guillain-Barre Syndrome (GBS) Epidemiology Scenario in the 7MM (2020-2034)
- 7.4. United States Epidemiology
- 7.4.1. Guillain-Barre Syndrome (GBS) Epidemiology Scenario in the United States (2020-2034)
- 7.5. EU-5 Country-wise Epidemiology
- 7.5.1. Germany Epidemiology
- 7.5.1.1. Guillain-Barre Syndrome (GBS) Epidemiology Scenario in Germany (2020-2034)
- 7.5.2. France Epidemiology
- 7.5.2.1. Guillain-Barre Syndrome (GBS) Epidemiology Scenario in France (2020-2034)
- 7.5.3. Italy Epidemiology
- 7.5.3.1. Guillain-Barre Syndrome (GBS) Epidemiology Scenario in Italy (2020-2034)
- 7.5.4. Spain Epidemiology
- 7.5.4.1. Guillain-Barre Syndrome (GBS) Epidemiology Scenario in Spain (2020-2034)
- 7.5.5. United Kingdom Epidemiology
- 7.5.5.1. Guillain-Barre Syndrome (GBS) Epidemiology Scenario in the United Kingdom (2020-2034)
- 7.5.6. Japan Epidemiology
- 7.5.6.1. Guillain-Barre Syndrome (GBS) Epidemiology Scenario in Japan (2020-2034)
8. Treatment Algorithm, Current Treatment, and Medical Practices
- 8.1. Guillain-Barre Syndrome (GBS) Treatment and Management
- 8.2. Guillain-Barre Syndrome (GBS) Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Guillain-Barre Syndrome (GBS) Treatment
11. Marketed Products
- 11.1. List of Marketed Products in the 7MM
- 11.2. Drug Name: Company Name
- 11.2.1. Product Description
- 11.2.2. Regulatory Milestones
- 11.2.3. Other Developmental Activities
- 11.2.4. Pivotal Clinical Trials
- 11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Emerging Therapies
- 12.1. Key Cross
- 12.2. Drug Name: Company Name
- 12.2.1. Product Description
- 12.2.2. Other Developmental Activities
- 12.2.3. Clinical Development
- 12.2.4. Safety and Efficacy
- 12.2.5. Product Profile
List to be continued in report
13. Guillain-Barre Syndrome (GBS): Seven Major Market Analysis
- 13.1. Key Findings
- 13.2. Guillain-Barre Syndrome (GBS) Market Size in 7MM
- 13.3. Guillain-Barre Syndrome (GBS) Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
- 15.1. United States: Market Size
- 15.1.1. Guillain-Barre Syndrome (GBS) Total Market Size in the United States
- 15.1.2. Guillain-Barre Syndrome (GBS) Market Size by Therapies in the United States
- 15.2. EU-5 countries: Market Size and Outlook
- 15.3. Germany Market Size
- 15.3.1. Guillain-Barre Syndrome (GBS) Total Market Size in Germany
- 15.3.2. Guillain-Barre Syndrome (GBS) Market Size by Therapies in Germany
- 15.4. France Market Size
- 15.4.1. Guillain-Barre Syndrome (GBS) Total Market Size in France
- 15.4.2. Guillain-Barre Syndrome (GBS) Market Size by Therapies in France
- 15.5. Italy Market Size
- 15.5.1. Guillain-Barre Syndrome (GBS) Total Market Size in Italy
- 15.5.2. Guillain-Barre Syndrome (GBS) Market Size by Therapies in Italy
- 15.6. Spain Market Size
- 15.6.1. Guillain-Barre Syndrome (GBS) Total Market Size in Spain
- 15.6.2. Guillain-Barre Syndrome (GBS) Market Size by Therapies in Spain
- 15.7. United Kingdom Market Size
- 15.7.1. Guillain-Barre Syndrome (GBS) Total Market Size in the United Kingdom
- 15.7.2. Guillain-Barre Syndrome (GBS) Market Size by Therapies in the United Kingdom
- 15.8. Japan Market Outlook
- 15.8.1. Japan Market Size
- 15.8.2. Guillain-Barre Syndrome (GBS) Total Market Size in Japan
- 15.8.3. Guillain-Barre Syndrome (GBS) Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Guillain-Barre Syndrome (GBS)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
- 20.1. Bibliography
- 20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
The table of contents is not exhaustive; the final content may vary.
